to take a little off the table!!!! the crazy
analyist have hyped a good solid company a little to
much....agn multiple now higher than most pure plays in
pharmaceuticals(exception being the ones thought to be in play),and
remember folks this aint no pure pharm play...the
derm,contact lens solution and medical device businesses do
not deserve anything close to 40 times 1999
eps....how about 15 or 20???....in any event,agn is a great
company long term ,but it isnt worth anything close to
What are the basic criteria that a company uses
to decide whether to split their stock.
originally thought the AGN stock would've split when it
reached the $80's. Now it's over $100. What is AGN's
board waiting for?
dont look now but coo is currently at 15.5 1999
concensus eps(1.50)....not that i am happy,but our whole
sector is under fire due to the ocular ssience
problem...in fact we have the highest multiple of anyone
else(wj is at 14 and ocular is now 10)...hopefully we can
get the street to find intrest in contact lens
companies in the future...lets all have fun and watch the
remarkable grouth of agn.
by who's standard do you think is a fair
value...would like to see your model for valuation...not trying
to argue,but just would like to see how you value a
company like agn who has two non pharm pieces that
represent about 50% of their business,neither growing
much(lenscare down and surgical up less than 5%),in industry
sectors giving multipules less than 20 times 1999 eps
projections....agn pharm peers(like merck are now getting 40 times
1999 eps...i still think agn looks rich to
Tears lubricate and moisten the cornea - the
clear "window" to the lens. If your cornea dries out
and/or become abraded and infected you will become
blind. Dry eyes are a big deal.
Red Dwarf MD
This drug has nothing to do with losing eyesight.
It's for dry eye. Yes very uncomfortable, but not
sight threatening. The drug will probably also be used
for allergies. Not sight threatening here either.
It's obvious that you are not an ophthalmologist.
If you were you would clearly understand the niche
market that Restasis will fit into. Oh, and by the way,
cyclosporin is not the most comfortable medication there is